Print

Elekta: U.S. Patients and Clinics to Benefit from New Revolutionary Beam-Shaping Device  
6/14/2012 11:30:37 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Elekta (STO:EKTAB) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Agility™*, a revolutionary beam-shaping device integrated into the head of a linear accelerator (linac). Patients and clinics in the US will now be able to benefit from the speed and reliability of this new MLC design. Elekta has collaborated closely with leading hospitals and research institutions to develop a solution that can increase the throughput of patients while delivering outstanding precision.
//-->